Introduction
Genetic mutations or variations in cancer cells can occur either at the single nucleotide level, resulting in point mutations, i.e., single nucleotide polymorphisms (SNPs), or at the chromosomal level, resulting in translocation, deletions, amplification and whole chromosome aneuploidy. Such mutations may cause heterogeneity in the behavior of cancer cells, driving events leading to the development of tumor cell invasion and metastasis and thus, contributing to the prognosis of cancer patients. The course of tumor metastasis entails a series of stages that lead to the formation of secondary tumors in distant organs. Metastasis is the most challenging and fatal phase of neoplastic diseases and it accounts for 90% of cancerrelated deaths [1, 2] . Therefore, genetic mutations in metastasis-associated genes will undoubtedly have a profound impact on disease prognosis. However, our understanding of mutations in metastatic genes remains incomplete.
Numerous studies have shown that angiopoietin-like 4 (ANGPTL4) is a prominent gene associated with various tumor types and metastasis [3] [4] [5] [6] . Several factors, such as epidermal growth factor and oleic acid, have also been shown to induce expression of ANGPTL4 in head and neck squamous cell carcinoma, thereby enhancing anoikis and promoting invasion [7, 8] . Full-length ANGPTL4 protein is cleaved by pro-protein convertases, releasing the Nterminal coiled-coil fragment (nANGPTL4) and the monomeric C-terminal fibrinogen-like domain (cANGPTL4) [4, 9] . The nANGPTL4 fragment modulates circulating triglycerides by inhibiting lipoprotein lipase [10] . ANGPTL4-deficient mice have lower plasma triglyceride levels, whereas hepatic over-expression of ANGPTL4 causes hypertriglyceridemia, hepatic steatosis and reduced fat mass [11] [12] [13] . The expression of cANGPTL4 increases as the tumor progresses from a benign to a metastatic state. The cANGPTL4, but not full-length ANGPTL4, promotes the growth and invasiveness of various cancer types [5, [14] [15] [16] .
cANGPTL4 also stimulates integrin-mediated signaling and leads to the activation of
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4 PI3K/PKBα and ERK signaling cascades to confer anoikis resistance [15, 17, 18] . Tumorderived cANGPTL4 also acts in a paracrine manner to disrupt endothelial continuity, facilitating metastasis [19] [20] [21] .
Despite its involvement in cancer progression and metastasis, SNPs in ANGPTL4 have only been associated with metabolic diseases [22] [23] [24] [25] . SNPs in cANGPTL4 may significantly impact its pro-tumorigenic role. However, the consequences of such cANGPTL4 SNPs on the growth and metastatic potential of cancer cells remain unknown. In this study, we investigated the effects of cANGPTL4 SNP variants, specifically the T266M variant, on cancer cell behavior and the underlying mechanism.
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Materials and Methods

Cell culture. Human hepatocellular carcinoma HepG2 and gastric carcinoma MKN74
were routinely cultured in Dulbecco's modified Eagle's medium (DMEM) and RPMI supplemented with 10% FBS, respectively. Cells were maintained in a humidified incubator with 5% CO 2 at 37 °C. Liver and gastric cancers were chosen for this study because they represent the two most prevalent cancers in Asia. HepG2 and MKN74 are among the most common cell lines used for the study of liver and gastric cancers in literature, respectively.
These cell lines can form xenograft tumors which allow in vivo examination. In addition, the T266M mutation was found these tumor types.
Site-directed mutagenesis. Site-directed mutagenesis was performed using a QuikChange
Site-Directed Mutagenesis Kit (Agilent Technologies) based on the manufacturer's protocol.
All mutations were verified by DNA sequencing. The oligonucleotides used are listed in Table S1 .
Expression and purification of cAngptl4 mutants.
Recombinant protein expression and purification were performed as previously described [26, 27] . The mutant cANGPTL4 recombinant proteins were then concentrated using 10 kDa cut-off polyethersulfone membrane Vivaspin tubes (GE Healthcare).
Circular dichroism.
CD spectra for the proteins were collected using a Jasco J810 spectropolarimeter at 25 °C. For each protein sample (0.1 mg/ml in 20 mM PO 4 buffer, pH 7.0), 600 μL fractions were placed in a 1 cm path length cell, and data were collected from 250 nm to 190 nm at a scanning speed of 100 nm/min.
Infrared immunoblotting. Equal amounts of protein lysates were resolved by SDS-PAGE
and electrotransferred onto Immobilon-FL polyvinylidene fluoride membranes (Merck
Millipore). Infrared immunoblotting was performed as previously described [17] . Committee (ARF-SBS/NIE-A0250AZ) of Nanyang Technological University, Singapore.
Glucose uptake assay.
Briefly, cells were incubated with 10 µM of 2-NBDG for 12 h.
The cells were then harvested and subjected to FACS analysis using BD Accuri C6 flow cytometer (BD Biosciences, USA). Data was analysed using FlowJo and plotted based on mean intensity. 
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Surface plasmon resonance (SPR).
A BIAcore 3000 system (GE Healthcare) was used to examine the interactions among the various cANGPTL4 proteins and integrin 51, as previously described [27] . Human recombinant integrin α5β1 (R&D Systems) was immobilized onto a CM5-carboxylated dextran sensor chip (GE Healthcare) via amine
coupling. An anti-β1 integrin antibody against immobilized integrin 5β1 was used to determine the R max value of 4039.1 resonance units (RU). A neutralizing monoclonal antibody against cANGPTL4 was purified as previously described [15, 21] 2.11 CRISPR gene deletion. CRISPR-based gene deletion was performed as previously described [31] . Briefly, a pair of CRISPR DNA oligonucleotides targeting the first exon of human ANGPTL4 (CGGAGCACCGCTCATCCTCTTAGGTAGCCT) was annealed and cloned into pX260-U6-DR-BB-DR-Cbh-NLS-hSpCas9-NLS-H1-shorttracr-PGK-puro, which A C C E P T E D M A N U S C R I P T were purchased from Dharmacon. MKN28 cells were transfected with the siRNA using DharmaFect 1 according to the manufacturer's recommendation.
2.14 Anoikis assay. Anoikis assay was performed as previously described [15, 33] . Briefly, cells were seeded and treated with various concentrations of the recombinant cANGPTL4
protein for 12 h in serum-free DMEM before anoikis assay. Cognate vehicle treatment was included as a control. During the assay, 5.0 × 10 5 cells were detached and seeded onto serumfree DMEM equilibrated agarose. Cells were harvested at the indicated time points and analyzed for apoptosis via FACS analysis following Annexin V/PI staining.
A C C E P T E D M A N U S C R I P T Un-migrated cells on the upper membrane of the culture inserts were removed using cotton buds. The inserts were rinsed with PBS and subsequently stained in 0.1% crystal violet for 25
min. The inserts were thoroughly rinsed with PBS and then immersed in 500 µL of 0.5%
Triton-X solution overnight in the dark. The absorbance of each of the solutions at 595 nm was then measured using a NanoDrop 2000 spectrophotometer (Thermo Scientific). The absorbance difference between the test and control wells was used as an index for the comparison of cellular migration.
Kinase inhibitor array.
Kinase inhibitor array screen was performed as described [34] .
Briefly, 4x10 3 cells were seeded in each well of a 96-well plate and serum starved overnight.
Each kinase inhibitor from the SYNlibrary 95 inhibitor array (SYN-2103, SynKinase) was then added to a pair of wells-one control and the other treated with 5 μg/ml cANGPTL4.
Total RNA from each sample was extracted and reverse transcribed to cDNA using iScript™ cDNA Synthesis Kit (Bio-Rad). qPCR was performed to determine the expression levels of various Gluts with the Bio-rad thermocycler. The Glut2 primers used were: Forward primer: 
Statistical analysis.
Statistical analyses were performed using two-tailed Mann-Whitney tests with Prism software. P <0.05 was considered significant.
Results
The cANGPTL4 T266M variant has a reduced binding affinity for α5β1 integrin.
The sequencing of the human ANGPTL4 gene from >1000 human cancer cell lines (Broad-Novartis Cancer Cell Lines Encyclopedia; www.broadinstitute.org/ccle/home) and ~8000 unique tumor samples (Wellcome Trust Sanger Institute COSMIC database) unveiled 13 distinct missense SNPs in the gene coding region of cANGPTL4 (Fig. 1A) . Other than the
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T266M SNP, the remaining SNPs were not observed in an earlier population-based sequencing of the ANGPTL4 gene. cANGPTL4 binds to the α5β1 integrin, affecting several downstream signaling pathways that mediate motility and survival [5, 15, 27] . Thus, we questioned whether the T266M cANGPTL4 variant has an altered affinity for integrin. We first expressed recombinant wild-type (wt) cANGPTL4 and its T266M variant using a bacterial expression system before purifying it with Ni-NTA affinity chromatography using This reduced binding affinity of T266M cANGPTL4 for integrin was not due to a major conformational distortion of the protein, as the T266M SNP did not alter the overall secondary structure of the protein, which comprised largely of β sheets, according to the circular dichroism (CD) spectra analysis ( Supplementary Fig. S1B ) [37] . Unlike the T266M
variant, the SPR analysis of the remaining 12 SNPs in cANGPTL4 binding for integrin α5β1
revealed only a modest 2-to 5-fold decrease in binding affinity when compared to wt cANGPTL4 (Table 1) . Thus, we performed subsequent investigations using the T266M and wt cANGPTL4 proteins. In addition to integrin α5β1, cANGPTL4 also interacts with other surface proteins such as claudin-5 and VE-cadherin to activate downstream pathways involved in metastasis [21] .
Binding affinity fold-change Wild-Type Table 1 . Binding affinity for the various cANGPTL4 mutations against α1β5 integrin.
Values (means ± SEM) of n=3 independent experiments. The association (k a ) and dissociation (k d ) rate constant were determined independently from the association and dissociation phases, respectively, with six different concentrations of analytes onto the integrin immobilized sensor chip. Affinity constant (K D ) corresponds to the k d /k a ratio.
We used a cell-based binding assay (LigandTracer ® Green) to investigate whether the T266M variant has an overall reduced affinity to its interacting proteins on the cell surface.
Fluorescein isothiocyanate (FITC) was conjugated to T266M and wt cANGPTL4 proteins via primary amines. We observed an increase in the fluorescence signal retained in the cells
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13 when FITC-conjugated wt cANGPTL4 was added to the culture medium ( Supplementary   Fig. 1C ). The presence of a neutralizing monoclonal antibody against cANGPTL4 reduced the fluorescence signal back to the basal level ( Supplementary Fig. 1C ). The specificity and neutralization function of the monoclonal antibody has been previously demonstrated [15, 17, 27, 38] . The antibody blocked the interaction between cANGPTL4 and its various interacting partners on the cell surface. An isotype-matched control IgG had no effect. We monitored the association and dissociation of the T266M and wt cANGPTL4 proteins to their cell surface receptors at various protein concentrations (0.3, 0.15, and 0.075 mg/ml) ( Supplementary Fig. S1C ). However, we were unable to obtain an acceptable fit of the binding response curves using a Langmuir 1:1 model and thus, we were not able to determine the affinities for the two interactions. Nevertheless, if the active concentrations of both wt and mutant proteins were similar, we observed a decrease of ~60% in the binding signal of the T266M variant when compared to wt cANGPTL4, suggesting a change in the affinity of the interaction. This difference in affinity may exert an important effect on the activation of various downstream signaling pathways, and consequently, the tumorigenicity of cancer cells with the T266M SNP.
Reduced activation of downstream signaling by the cANGPTL4 T266M variant.
cANGPTL4 activates the PI3K/PKBα and ERK signaling cascades to confer anoikis resistance and invasiveness [14] [15] [16] . To investigate how the T266M variant affects these signaling cascades, we first generated an ANGPTL4-depleted HepG2 cell line (C10) using a Crispr/Cas9 approach and a T266M cANGPTL4 variant expressing C10 HepG2 cell line (C10 T266M ) via the stable transfection of a mammalian expression plasmid harboring cDNA encoding for T266M cANGPTL4. Western blot analysis revealed an 82% reduction in endogenous cANGPTL4 in the C10 HepG2 cells. We have analyzed the entire genome for high potential off-target sites, other than ANGPTL4. Using surveyor nuclease assay, we
showed that there were no off-target site mutation, as evidenced by the absence of digested DNA fragment (Supplementary Fig. S1D ). We were unable to maintain any ANGPTL4-null C10 HepG2 line beyond 3 passages. Two independent C10 T266M HepG2 clones expressing similar levels of cANGPTL4 to wt HepG2 were isolated for the subsequent in vivo analysis study ( Supplementary Fig. S1D ). Due to glycosylation, endogenous cANGPTL4 had a higher molecular weight than the recombinant cANGPTL4, as previously observed ( Supplementary   Fig. S1A ) [39] . As cANGPTL4 is a secreted protein, we also detected cANGPTL4 in the culture medium of HepG2 cells, C10 HepG2 cells and C10 T266M HepG2 cells ( Supplementary   Fig. S1E ).
Next, we examined the levels of phosphorylated ERK (p-ERK) and AKT (p-AKT) in C10 and wt HepG2 cells at 0 and at 6 hours after anoikis challenge. The levels of p-ERK and p-AKT were lower in the C10 HepG2 cells than in the wt HepG2 cells ( Fig. 2A-D) . The addition of recombinant wt cANGPTL4 protein increased the p-ERK and p-AKT levels in a dose-dependent manner ( Fig. 2A-D) . Notably, T266M cANGPTL4 protein also increased p-ERK and p-AKT levels, albeit to a smaller extent ( Fig. 2A-D) . We repeated the same experiments with another cancer cell type, gastric adenocarcinoma MKN74 cells, whose endogenous ANGPTL4 expression can be suppressed by doxycycline-induced shRNA (MKN74 ANGPTL4 ), and we observed similar trends ( Supplementary Fig. S2 ). These observations suggest that the T266M cANGPTL4 protein has a weaker capacity to activate downstream signaling pathways for survival and invasiveness.
Cancer cells expressing T266M cANGPTL4 are less metastatic.
The roles of cANGPTL4 in the multistep processes of metastasis, which include tumor growth, anoikis resistance and invasiveness, have been well established [4, 5, 40] . Based on transwell migration assays, we found that ANGPTL4-deficient C10 HepG2 cells have impaired transwell migration compared to wt HepG2 cells, as observed from the reduced number of fluorescence-stained cells (Fig. 3A) . A dose-dependent increase in transwell migration was observed when C10 cells were treated with recombinant wt cANGPTL4. Notably, when C10 cells were treated with T266M cANGPTL4, the number of invading cells was lower than those treated with wt cANGPTL4 protein (Fig. 3A) . The C10 cells were also more susceptible to anoikis after six hours in suspension than wt HepG2 cells (Fig. 3B) .
Treatment with exogenous recombinant wt cANGPTL4 protein conferred anoikis resistance in the C10 cells in a dose-dependent manner ( Fig. 3C-D) . This rescue effect was diminished when recombinant T266M cANGPTL4 was used ( Fig. 3C-D) . Similar observations were also obtained when transwell and anoikis assays were performed using MKN74 ANGPTL4 .
Consistently, the recombinant wt cANGPTL4 was more effective in rescuing the impaired invasiveness ( Supplementary Fig. S3A ) and the increased anoikis susceptibility (Fig. 4A) . The C10 T266M -derived tumors exhibited sizes that were between the sizes of the C10 and wt tumors (Fig. 4A) . Immunofluorescence staining of the various tumor xenografts for Ki67 protein, a cellular proliferation marker, showed that wt HepG2-derived tumors had the most Ki67-positive cancer cells, whilst the C10-derived tumors had the least (Fig. 4B-C) . Consistently, the C10 T266M -derived tumors had an intermediate number of Ki67-positive cancer cells (Fig. 4B-C) . Apoptotic cells were assessed via in situ TUNEL staining.
The TUNEL assays revealed an inverse profile to that of the Ki67 protein assay. The C10-derived tumors had the highest number of apoptotic cancer cells, followed by the C10 T266M -derived tumors and the wild-type HepG2-derived tumors (Fig. 4B-C) . Consistent with the in vitro observations, we also observed that the wt HepG2-derived tumors had elevated levels of p-ERK and p-AKT, followed by the C10 T266M -derived tumors, and that the C10-derived tumors had reduced p-ERK and p-AKT levels ( Fig. 4D-G ).
These observations indicated that the weaker affinity of T266M cANGPTL4 for integrin reduces tumor growth, which is associated with diminished proliferation, increased apoptosis, and reduced activation of the PI3K/PKBα and ERK pathways compared to wt cANGPTL4.
cANGPTL4 modulates glucose uptake.
To proliferate and migrate, cancer cells must comply with the energy demand imposed by vital processes such as DNA replication and cytoskeleton remodeling. While ANGPTL4 plays a well-established role in peripheral glucose and lipid metabolism [4, 10] , its role in cellular metabolism is unclear. Thus, we examined whether cANGPTL4 affects cellular glucose metabolism. Glucose uptake was monitored via FACS following the uptake of 2-(N-
glucose analog that will not be metabolized and is an indicator of direct glucose uptake by the cells [41] . We observed that the cANGPTL4-deficient C10 HepG2 cells exhibited reduced glucose uptake, which was partially restored when treated with recombinant wt cANGPTL4 (Fig. 5A) . However, treatment with the recombinant T266M cANGPTL4 variant restored glucose uptake to a lesser extent. To further confirm this observation, we also examined whether wt and C10-derived tumors affect in vivo glucose uptake. To this end, we utilized a fluorescent optical imaging agent, IRDye ® 800CW 2-deoxyglucose. Mirroring the data
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19 observed for glucose uptake in vitro, wt HepG2-derived tumors showed the strongest fluorescent signal, followed by the C10 T266M -derived tumors, whereas the C10-derived tumors had the weakest signal ( Fig. 5B-C) . These observations suggest that cANGPTl4 modulates cellular glucose uptake. 
cANGPTL4 modulates GLUT2 expression.
Next, we first determined the expression of key glucose transporters in wt HepG2, whose expression was modulated by recombinant wt cANGPTL4. Except for Glut2, all other examined Gluts were unchanged by wt cANGPTL4 as determined by qPCR (Fig. 6A) . We also observed that C10 HepG2 cells have lower Glut2 expression compared with wild-type HepG2 cells (Fig. 6A) . Importantly, the treatment with recombinant T266M cANGPTL4 on C10 cells was less effective in increasing the expression of Glut2 than wild-type cANGPTL4 protein (Fig. 6B) . These findings were similarly observed in ANGPTL4 siRNA knockdown of HepG2 and MKN 74 cancer cells (Supplementary Fig. S4 ), suggesting that ANGPTL4-
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21 mediated Glut2 expression is not restricted to liver cancer. Next, we sought to elucidate the mechanism whereby cANGPTL4 upregulates Glut2 expression. We subjected cANGPTL4-stimulated wt HepG2 to a kinase inhibitor array screen to identify key signaling pathways involved in the cANGPTL4-mediated up-regulation of Glut2. Glut2 expression was increased when cells were treated with cANGPTL4. Hence, we reasoned that kinase inhibitors that negated or inhibited the cANGPTL4-mediated up-regulation of Glut2 mRNA transcript indicated the involvement of those specific kinases in the selected signaling cascades.
Conversely, kinase inhibitors that did not attenuate the cANGPTL4-mediated up-regulation of Glut2 would indicate that those kinases were not involved in cANGPTL4-mediated signaling ( Supplementary Fig. S5A ). Our results showed that inhibitors against SRC, 
Increased adenylate energy charge by cANGPTL4.
To investigate whether the increased glucose uptake results in a concomitant change in cellular metabolism, we measured the adenylate energy charge status of the cells, which is indicative of cellular metabolic activities [45, 46] . We first determined the retention time of the individual AMP, ADP and ATP standards by high-performance liquid chromatography (HPLC) before analyzing the cell lysates of the C10, C10 T266M and wt HepG2 cells ( Supplementary Fig. S7A ). We then calculated the energy charge (EC) ratio for each cell type. We found that the EC for the C10 cells was approximately 3-fold lower than that of the wt HepG2 (Fig. 7A ). Upon treatment with recombinant wt cANGPTL4, the EC of the C10 cells increased to a level that nearly reached that of the wt cells. However, only a partial rescue was achieved when the C10 cells were treated with an identical dose of T266M cANGPTL4 (Fig. 7A) . Next, we determined the EC of the wt HepG2-and C10 T266M -derived tumors using HPLC ( Supplementary Fig. S7B-D) . Similarly, we detected higher EC in wt HepG2-derived tumors compared with C10 T266M -derived tumors (Fig. 7B ).
Using matrix assisted laser desorption/ ionization-mass spectrometry imaging (MALDI-MSI), we examined the EC distribution of each type of tumor. The spectrum profiles of the AMP, ADP and ATP standards were first determined ( Supplementary Fig.   S7E ). The spatial profiles of AMP, ADP and ATP were first determined to obtain the EC distribution for the various tumor xenografts ( Fig. 7C and Supplementary Fig. S8 ). More EC hotspots were particularly localized to the outermost periphery of the wt HepG2-derived tumors in two different regions. Fewer EC hotspots were observed for the C10-and C10 T266M -derived tumors (Fig. 7C) . Interestingly, these EC hotspots were largely localized at
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
24 the tumor peripheral. The H&E images of consecutive sections confirmed that the areas with low EC were not due to cell apoptosis (Fig. 7C ). This observation was consistent with the earlier in vitro finding that the cancer cells expressing wt cANGPTL4 exhibited increased invasiveness compared to cancer cells deficient for T266M cANGPTL4 and ANGPTL4.
Collectively, our observations suggest that cANGPTL4 modulates tumor growth and cellular metabolism and that an SNP at amino acid 266 from threonine to methionine reduces the metabolic properties necessary for cell growth and migration. 
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Discussion
In cancer research, SNPs have proven to be an important factor in determining susceptibility and the prognostic information of cancer [47] . Herein, we examined SNPs in the metastasis-associated ANGPTL4 gene, specifically in the region coding for the C-terminal domain of ANGPTL4. Our study indicates that cANGPTL4 plays a role in cellular metabolism and that the T266M cANGPTL4 variant has an impact on several aspects of metastasis.
Using clinical, functional, and molecular evidence, cANGPTL4 has been shown to regulate the metastatic potential of numerous cancers [15, 48, 49] . Human ANGPTL4 expression is up-regulated by TGF and HIF. The induction of ANGPTL4 primes tumor cells for the disruption of endothelial junctions required for distant colonization [15, 19, 21, 48, 49] .
In addition, cANGPTL4 plays a pivotal role in vascular leakiness, anoikis resistance and invasiveness [14] [15] [16] 21, 50] . The cANGPTL4 protein interacts with specific integrins to activate the downstream ERK and PI3K pathways for invasiveness and survival. cANGPTL4
also instigates the disruption of endothelial continuity by directly interacting with integrin α5β1, VE-cadherin, and claudin-5 in a temporally sequential manner, thus facilitating metastasis [21] . We identified that the T266M cANGPTL4 variant protein interacted with Population-based sequencing of the ANGPTL4 gene revealed that ~3% of people of European ancestry are carriers of an E40K variant. The E40K mutation, which resides in nANGPTL4, significantly impairs the ability of ANGPTL4 to inhibit LPL by destabilizing or impairing the production of ANGPTL4 [51, 52] . Consistent with the role of ANGPTL4 as an LPL inhibitor, carriers of the E40K variant are associated with lower plasma triglyceride levels [24] and, in some studies, higher high-density lipoprotein levels than non-carriers [46] .
A recent study also showed that E40K carriers have a lower risk of coronary heart disease (CHD) [47] . The association of a more common coding variant, T266M, to plasma triglycerides and CHD remain unclear. Several reports have suggested an association between lower plasma triglycerides and CHD risk, whereas a meta-analysis of four studies suggested no association [23, 24, 44, 48] . Importantly, the mechanism by which T266M cANGPTL4 affects cellular metabolism remains unclear. In addition, cANGPTL4 does not interact with LPL to affect lipid metabolism [49] . In this study, we showed that cANGPTL4 affects Figure 3 and Supplementary Fig. S3 .
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